Trial Profile

A Phase 1 Clinical Study of Autologous TCR-T Cells (SCG142) Therapy for Advanced HPV Associated Carcinomas

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 27 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SCG 142 (Primary)
Indications Carcinoma
Focus Adverse reactions; First in man

Most Recent Events

18 Oct 2025 According to SCG Cell Therapy Media Release, data from the trial were presented at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, on Saturday, 18 October 2025.
18 Oct 2025 Results published in the SCG Cell Therapy Media Release
13 Aug 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com